Dr. Sehouli Discusses Trial of Secondary Cytoreductive Surgery in Ovarian Cancer
Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, discusses a trial of secondary cytoreductive surgery in patients with ovarian cancer, presented at the 2017 International Meeting of the European Society of Gynaecological Oncology (ESGO).
Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité — Universitatsmedizin Berlin, discusses a trial of secondary cytoreductive surgery in patients with ovarian cancer, presented at the 2017 International Meeting of the European Society of Gynaecological Oncology (ESGO).
Sehouli says that surgery is the cornerstone of primary treatment for ovarian cancer, followed by subsequent chemotherapy with platinum combinations. The role of surgery in the relapsed setting is not as defined though, Sehouli adds.
In a randomized controlled phase III study, secondary cytoreductive surgery was evaluated in patients with platinum-sensitive recurrent ovarian cancer.
